Usefulness of whole blood aggregometry and its comparison with thromboxane generation assay in monitoring acetylsalicylic acid effectiveness - A multiparametric study in rats

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 7, 2006, Pages 853-862

  Nocun, Marek ^a   Golanski, Jacek ^a   Lapshina, Elena ^b   Zavodnik, Leu ^b   Dobaczewski, Marcin ^a   Kazmierczak, Piotr ^a   Markuszewski, Leszek ^a   Zavodnik, Ilya ^b   Watala, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF BIOCHEMISTRY   (Belarus)

Author keywords

Aspirin resistance; Monitoring of platelet response to acetylsalicylic acid (ASA); Platelet function tests; Thromboxane generation; Whole blood aggregometry

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1; HIRUDIN; LASPAL; LEPIRUDIN; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; ENZYME INHIBITION; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STANDARD; THROMBOCYTE AGGREGATION; THROMBOXANE GENERATION ASSAY; WHOLE BLOOD AGGREGOMETRY;

ADENOSINE DIPHOSPHATE; ANIMALS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL AGGREGATION; COLLAGEN; MALE; NEPHELOMETRY AND TURBIDIMETRY; PLATELET AGGREGATION; RATS; RATS, WISTAR; THROMBOXANES; TIME FACTORS;

ANIMALIA;

EID: 33745221419     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.157     Document Type: Article

References (45)

1. Halgson CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-50.
2. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258-63.
3. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005;42:99-103.
4. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responders and aspirin non-responders. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
5. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
6. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
7. Cox D, Fitzgerald D. Monitoring antiplatelet therapy. In: Gresele P, Page CP, Fuster V, Vermylen J, editors. Platelets in thrombotic and non-thrombotic disorders. Cambridge: Cambridge University Press, 2002:471-84.
8. Steinhubl SR, Charnigo R, Moliterno DJ. Resistance to antiplatelet resistance is it justified? J Am Coll Cardiol 2005;45:1757-8.
9. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-9.
10. Steinhubl SR, Varinasi JS, Goldberg L. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;42:1336-7.
11. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005;101:71-6.
12. Golanski J, Nocun M, Rozalski M, Drygas W, Watala C. An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis 2004;15:187-95.
13. Hart RG, Leonard AD, Talbert RL, Pearce LA, Cornell E, Bovill E, et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 2003;23:579-84.
14. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
15. De La Cruz JP, Moreno A, Munoz M, Garcia Campos JM, Sanchez De La Cuesta F. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J Pharmacol Exp Ther 1997;280:454-9.
16. Judge S, Mammen E, Dunbar JC. The effect of streptozocin-induced diabetes on platelet aggregation as determined by impedance aggregometry and platelet secretion: a possible role for nitric oxide. J Assoc Acad Minor Phys 1995;6:100-4.
17. Kurata M, Ishizuka N, Matsuzawa M, Haruta K, Takeda K. A comparative study of whole-blood platelet aggregation in laboratory animals: its species differences and comparison with turbidimetric method. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995;112:359-65.
18. Imbault P, Doutremepuich F, Aguejouf O, Doutremepuich C. Antithrombotic effects of aspirin and LMWH in a laser-induced model of arterials and venous thrombosis. Thromb Res 1996;82:469-78.
19. Watala C, Ulicna O, Golanski J, Nocun M, Waczulikova I, Markuszewski L, et al. High glucose contributes to aspirin insensitivity in streptozotocin- diabetic rats - a multiparametric aggregation study. Blood Coagul Fibrinolysis 2006;17:113-24.
20. Jilma B, Fuchs I. Aspirin. Methods to assess aspirin resistance. J Thromb Haemost 2004;2:337-8.
21. Richards EM, Baglin TP. Quantitation of reticulated platelets: methodology and clinical application. Br J Haematol 1995;91:445-51.
22. Svenstrup PT, Risom KS, Atar D, Mickley H. A critical appraisal of the phenomenon of aspirin resistance. Cardiology 2005;104:83-91.
23. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-32.
24. Golanski J, Chlopicki S, Golanski R, Gresner P, Iwaszkiewicz A, Watala C. Resistance to aspirin in patients after coronary artery bypass grafting in transient-impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit 2005;27:484-90.
25. Lellouche F, Fradin A, Fitzgerald G, Maclouf J. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 1990;40:297-310.
26. Murphy RC, FitzGerald GA. Current approaches to estimation of eicosanoid formation in vivo. Adv Prostaglandin Thromboxane Leukot Res 1994;22:341-8.
27. Zar J, editor. Biostatistical analysis, 4th ed. Engelwood Cliffs, NJ: Prentice-Hall International, 1999.
28. Watala C, Golanski J, Pluta J, Bonder M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb Res 2004;113:101-13.
29. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005;83:148-58.
30. Aguejouf O, Malfatti E, Belon P, Doutremepuich C. Time related neutralization of two doses of acetyl salicylic acid. Thromb Res 2000;100:317-23.
31. Wallen NH, Ladjevardi M, Albert J, Broijersen A. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. Thromb Res 1997;87:151-7.
32. De La Cruz P, Guerrero A, Paniego J, Arranz I, Moreno A, Sanchez De La Cuesta F. Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy. Naunyn Schmiedebergs Arch Pharmacol 2002;365:96-101.
33. Sharp PE, La Regina MC. Important biological features. In: Suckow MA, editor. The laboratory rat. New York: CRC Press, 1998:1-20.
34. Dwyer SD, Meyers KM. Anesthetics and anticoagulants used in the preparation of rat platelet-rich-plasma alter rat platelet aggregation. Thromb Res 1986;42:139-51.
35. Takahashi O. Characteristics of rat platelets and relative contributions of platelets and blood coagulation to haemostasis. Food Chem Toxicol 2000;38:203-18.
36. De La Cruz JP, Villalobos MA, Escalante R, Guerrero A, Arrebola MM, Sanchez De La Cuesta F. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction. Br J Pharmacol 2002;137:1082-8.
37. Faraday N, Scharpf RB, Dodd-o JM, Martinez EA, Rosenfeld BA, Dorman T. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001;94:145-51.
38. De Meijer A, Vollaard H, De Metz M, Verbruggen B, Thomas C, Novakova I. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther 1999;66:425-30.
39. Cerletti C, Gambino MC, Garattini S, De Gaetano G. Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels. J Clin Invest 1986;78:323-6.
40. Wallace JL, Muscara MN, McKnight W, Dicay M, Del Soldato P, Cirino G. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Thromb Res 1999;93:43-50.
41. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995;96:2711-8.
42. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-18.
43. Sathiropas P, Marbet GA, Sahaphong S, Duckert F. Detection of small inhibitory effects of acetylsalicylic acid (ASA) by platelet impedance aggregometry in whole blood. Thromb Res 1988;51:55-62.
44. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-9.
45. Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005;46:638-45.